Wells Fargo & Company Reaffirms Equal Weight Rating for Inozyme Pharma (NASDAQ:INZY)

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “equal weight” rating reaffirmed by equities research analysts at Wells Fargo & Company in a note issued to investors on Friday,Benzinga reports. They presently have a $4.00 price target on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 1.27% from the company’s previous close.

INZY has been the subject of a number of other reports. Wedbush reiterated an “outperform” rating and set a $7.00 price target (down from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. Jefferies Financial Group reiterated a “hold” rating and set a $4.00 price target (down from $15.00) on shares of Inozyme Pharma in a report on Friday. Piper Sandler lowered their price target on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Needham & Company LLC lowered their price target on shares of Inozyme Pharma from $15.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Inozyme Pharma in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.75.

Inozyme Pharma Stock Performance

Shares of INZY opened at $3.95 on Friday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a market cap of $255.02 million, a P/E ratio of -2.53 and a beta of 1.35. The company has a 50-day moving average of $1.09 and a two-hundred day moving average of $1.87. Inozyme Pharma has a 12-month low of $0.72 and a 12-month high of $6.24.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). As a group, research analysts predict that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Inozyme Pharma

Several institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in Inozyme Pharma during the first quarter worth approximately $72,000. ADAR1 Capital Management LLC lifted its position in shares of Inozyme Pharma by 15.1% during the first quarter. ADAR1 Capital Management LLC now owns 87,799 shares of the company’s stock worth $80,000 after purchasing an additional 11,500 shares in the last quarter. Pale Fire Capital SE lifted its position in shares of Inozyme Pharma by 101.7% during the first quarter. Pale Fire Capital SE now owns 440,807 shares of the company’s stock worth $401,000 after purchasing an additional 222,270 shares in the last quarter. Aberdeen Group plc lifted its position in shares of Inozyme Pharma by 91.6% during the first quarter. Aberdeen Group plc now owns 326,758 shares of the company’s stock worth $297,000 after purchasing an additional 156,236 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Inozyme Pharma during the first quarter worth $146,000. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.